F.O.C.U.S. in CML. Real-World Evidence (RWE) in Greece in patients with Chronic Myeloid Leukemia – Chronic Phase (CML-CP) who have already received at least one dose of Imatinib 600 mg following suboptimal response or failure to Imatinib 400 mg

Trial information

Medical condition

CML

Trial phase

Phase 4

Sponsor

Vocate Pharmaceutical

Start date

02/11/2026

End date

30/11/2027

Main objective

Major Molecular Response (MMR, BCR::ABL1 ≤0.1% per IS) rate at 12 months from baseline, in patients for whom the treating physician has already decided on dose escalation.

Locations and Contact points